Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
申请人:Bristol-Myers Squibb Company
公开号:US07378426B2
公开(公告)日:2008-05-27
Disclosed are fused heterotricyclic compounds of the following formula I,
or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of A ring or C ring is a 5-7 membered unsaturated heterocyclic ring. The disclosed compounds are useful as inhibitors of 17β-hydroxysteroid dehydrogenase 3 (17β-HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions comprising such compounds.
本发明公开了以下式I的融合异杂三环化合物,或其对映异构体、顺反异构体、互变异构体或药学上可接受的盐,其中A环或C环中的一个是5-7成员不饱和杂环环。所公开的化合物可用作17β-羟基类固醇脱氢酶3(17β-HSD3)的抑制剂。还公开了使用这些化合物治疗激素敏感性疾病,如前列腺癌的方法以及包含这些化合物的制药组合物。